minocycline hydrochloride · Journey · NDA 213690
Zilxi
Earliest generic entry, as listed
1 Oct 2030
Blocked by patent: US 10213512, US 10265404, US 10322186, US 10946101, US 12138311, US 12661407, US 8865139, US 8945516, US 8992896, US 9675700.
Listed patents · 10 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10213512 | product, use U-1631 | 1 Oct 2030 |
| US 10265404 | product | 1 Oct 2030 |
| US 10322186 | use U-1631 | 1 Oct 2030 |
| US 10946101 | use U-1631 | 1 Oct 2030 |
| US 12138311 | use U-1631 | 1 Oct 2030 |
| US 12661407 | use U-1631 | 1 Oct 2030 |
| US 8865139 | product, use U-1631 | 1 Oct 2030 |
| US 8945516 | product | 1 Oct 2030 |
| US 8992896 | product, use U-1631 | 1 Oct 2030 |
| US 9675700 | product, use U-1631 | 1 Oct 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213690 · 001 · RLD | aerosol, foam, topical | EQ 1.5% BASE | 1 Oct 2030 |